Possible side effects and treatments of Alpelisib

Alpelisib (Alpelisib)-Piqray, as a PI3K pathway inhibitor, has precise targets but may still cause a series of predictable adverse reactions. The most common side effects include hyperglycemia, rash, diarrhea, nausea, stomatitis and fatigue, etc. These reactions are mostly related to the drug mechanism. The PI3K signaling pathway is not only involved in tumor cell metabolism, but is also closely related to the regulation of normal insulin signaling. Therefore, increased blood sugar after taking the drug is one of the most representative side effects of Apelvis.

Some patients may experience elevated fasting blood sugar or even abnormal glucose tolerance, so blood sugar levels need to be monitored regularly during treatment. If blood sugar increases significantly, the doctor may adjust the diet, increase exercise, or use oral hypoglycemic drugs, such as metformin, to maintain metabolic stability.

Skin rashes and itching are also common problems, often related to an immune response. For mild to moderate rashes, antihistamines or topical corticosteroids can be used to relieve the symptoms; if the rash is large or accompanied by fever, the medication should be stopped in time and medical evaluation should be sought. Diarrhea may be caused by the inhibition of PI3K in intestinal epithelial cells. It is recommended that patients maintain adequate fluid intake, avoid spicy foods, and use antidiarrheal drugs under the guidance of a doctor.

In addition, apelvis may cause stomatitis, nausea, decreased appetite, and weight loss, which are usually relieved with supportive care. Rare but cautionary side effects include abnormal liver function, renal impairment, and allergic reactions. If jaundice, decreased urine output, or skin swelling occurs, the medication should be discontinued immediately and medical evaluation should be performed.

It is worth noting that the severity of side effects is related to individual differences, dosage and combination of medications. Clinical experience shows that reasonable monitoring and early intervention can significantly reduce the impact of adverse reactions and ensure continuity of treatment. The safety of Apelvis has been verified in multiple international studies, and most of its side effects can be resolved through dose adjustment, supportive treatment, or short-term drug withdrawal.

Reference materials:https://www.piqray.com/